Novo Nordisk to cut 9,000 jobs: Ozempic maker to reduce workforce by 11%; refocus on diabetes and obesity treatments
Novo Nordisk is set to reduce its workforce by 11%, eliminating 9,000 jobs globally, including 5,000 in Denmark, to save $1.3 billion amid rising competition for its obesity treatments. This restructuring follows a lowered earnings forecast and aims to streamline operations for growth in diabetes and obesity markets. Shares rose despite the announcement.🕒 1 min read
Novo Nordisk is set to reduce its workforce by 11%, eliminating 9,000 jobs globally, including 5,000 in Denmark, to save $1.3 billion amid rising competition for its obesity treatments. This restructuring follows a lowered earnings forecast and aims to streamline operations for growth in diabetes and obesity markets. Shares rose despite the announcement.
Continue Reading
- IPO this week: 10 offers to hit market including Crizac and Travel Food Services; SME segment dominates listings
-
‘Deep market’: Why is Rupee left to ‘find its correct level’? Governor Sanjay Malhotra explains stance as currency hovers near 90
- IPL 2026: Abhishek Sharma scripts history, equals Virat Kohli to become…
- Ukraine Downed Shahed Drones In Middle East During Iran War, Says Zelensky
-
UP Couple Returning After Distributing Son’s Wedding Card Dies In Accident
-
“Today, A Child Is Outsourced To Instagram”: Nara Lokesh On Parenting In Digital Age
-
All About Kid Cudi, Rapper Testifying At The Sean ‘Diddy’ Combs Trial
- 7 Maharashtrian Curries For Ganesh Chaturthi 2025 Celebrations
- When Delhi Rejected Virat Kohli For Pradeep Sangwan In IPL, Virender Sehwag Reveals Full Story
-
Why Guns N’ Roses Chose Guwahati As Its Next Show Stop In India